There are numbers available. At least rough or ballpark numbers. Back in 2018 there was suggestion that the total bolr liability if all advisers called it I was about $1.2 billion. That number also aligns with about 1,600 advisers amp or Hillross advisers having an average $720,000 of bolr liability based on $180k of applicable ongoing revenue.
they have probably got rid of nearly half the advisers but less than half the liability was involved as it was the below average ones exited. If these advisers who left are compensated - it may be for losing 40% of expectation with them having 30% of the liability. So about $150m there. Plus costs plus interest etc. $200m plus say. The remaining advisers may be due compensation as result of change in contract or not. Or it could be considered they have accepted new terms. I think there could be some costs here.
I have always seen a $300m cost as reasonable with a $500m tops. AMP should have been able to work this out. But understand why they would not disclose. They may in court to get collimate away.
- Forums
- ASX - By Stock
- AMP
- what's wrong with AMP?!
what's wrong with AMP?!, page-281
-
- There are more pages in this discussion • 205 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AMP (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.000(0.00%) |
Mkt cap ! $2.921B |
Open | High | Low | Value | Volume |
$1.13 | $1.15 | $1.12 | $9.055M | 8.008M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 75047 | $1.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 72779 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5387 | 1.120 |
6 | 209455 | 1.115 |
5 | 118243 | 1.110 |
3 | 82498 | 1.105 |
4 | 74710 | 1.100 |
Price($) | Vol. | No. |
---|---|---|
1.125 | 29688 | 4 |
1.130 | 149231 | 10 |
1.140 | 78285 | 5 |
1.145 | 518994 | 16 |
1.150 | 394541 | 47 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AMP (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online